#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=The rapid development of large-scale pharmaceutical manufacturing has contributed to increased concentrations of contaminants present in wastewater and surface waters .
3-1	17-20	The	event[3]	new[3]	_	_
3-2	21-26	rapid	event[3]	new[3]	_	_
3-3	27-38	development	event[3]	new[3]	_	_
3-4	39-41	of	event[3]	new[3]	_	_
3-5	42-53	large-scale	event[3]|abstract[4]	new[3]|new[4]	coref	4-8[0_4]
3-6	54-68	pharmaceutical	event[3]|abstract[4]	new[3]|new[4]	_	_
3-7	69-82	manufacturing	event[3]|abstract[4]	new[3]|new[4]	_	_
3-8	83-86	has	_	_	_	_
3-9	87-98	contributed	_	_	_	_
3-10	99-101	to	_	_	_	_
3-11	102-111	increased	animal[5]	new[5]	_	_
3-12	112-126	concentrations	animal[5]	new[5]	_	_
3-13	127-129	of	animal[5]	new[5]	_	_
3-14	130-142	contaminants	animal[5]|object	new[5]|new	_	_
3-15	143-150	present	animal[5]	new[5]	_	_
3-16	151-153	in	animal[5]	new[5]	_	_
3-17	154-164	wastewater	animal[5]|substance|substance[8]	new[5]|new|new[8]	coref|coref|coref|coref	6-19|11-18[74_8]|6-19|11-18[74_8]
3-18	165-168	and	animal[5]|substance[8]	new[5]|new[8]	_	_
3-19	169-176	surface	animal[5]|substance[8]|substance[9]	new[5]|new[8]|new[9]	_	_
3-20	177-183	waters	animal[5]|substance[8]|substance[9]	new[5]|new[8]|new[9]	_	_
3-21	184-185	.	_	_	_	_

#Text=Pharmaceutical wastewaters are produced during the drug manufacturing processes ( i. e. , fermentation , extraction , chemical synthesis , formulation , packaging and washing of solid cake and equipment ) .
4-1	186-200	Pharmaceutical	substance[10]	new[10]	_	_
4-2	201-212	wastewaters	substance[10]	new[10]	_	_
4-3	213-216	are	_	_	_	_
4-4	217-225	produced	_	_	_	_
4-5	226-232	during	_	_	_	_
4-6	233-236	the	abstract[12]	new[12]	appos	4-16[0_12]
4-7	237-241	drug	abstract[12]	new[12]	_	_
4-8	242-255	manufacturing	abstract|abstract[12]	giv|new[12]	coref	7-4[39_0]
4-9	256-265	processes	abstract[12]	new[12]	_	_
4-10	266-267	(	_	_	_	_
4-11	268-270	i.	_	_	_	_
4-12	271-273	e.	_	_	_	_
4-13	274-275	,	_	_	_	_
4-14	276-288	fermentation	substance	new	_	_
4-15	289-290	,	_	_	_	_
4-16	291-301	extraction	abstract	giv	appos	4-18[15_0]
4-17	302-303	,	_	_	_	_
4-18	304-312	chemical	abstract[15]	giv[15]	appos	4-21[0_15]
4-19	313-322	synthesis	abstract[15]	giv[15]	_	_
4-20	323-324	,	_	_	_	_
4-21	325-336	formulation	substance	giv	appos	4-23
4-22	337-338	,	_	_	_	_
4-23	339-348	packaging	abstract	giv	appos	4-25[18_0]
4-24	349-352	and	_	_	_	_
4-25	353-360	washing	abstract[18]	giv[18]	coref	16-14[105_18]
4-26	361-363	of	abstract[18]	giv[18]	_	_
4-27	364-369	solid	abstract[18]|object[19]	giv[18]|new[19]	_	_
4-28	370-374	cake	abstract[18]|object[19]	giv[18]|new[19]	_	_
4-29	375-378	and	abstract[18]	giv[18]	_	_
4-30	379-388	equipment	abstract[18]|object	giv[18]|new	_	_
4-31	389-390	)	_	_	_	_
4-32	391-392	.	_	_	_	_

#Text=Hence , the main pollution source of these pharmaceutical compounds in the environment is through industrial process water discharge .
5-1	393-398	Hence	abstract[24]|abstract[26]	new[24]|giv[26]	coref|coref	14-12[0_24]|14-12[0_24]
5-2	399-400	,	abstract[24]|abstract[26]	new[24]|giv[26]	_	_
5-3	401-404	the	abstract[24]|abstract[26]	new[24]|giv[26]	_	_
5-4	405-409	main	abstract[24]|abstract[26]	new[24]|giv[26]	_	_
5-5	410-419	pollution	abstract|abstract[24]|abstract[26]	new|new[24]|giv[26]	_	_
5-6	420-426	source	abstract[24]|abstract[26]	new[24]|giv[26]	_	_
5-7	427-429	of	abstract[24]|abstract[26]	new[24]|giv[26]	_	_
5-8	430-435	these	substance[22]|abstract[24]|abstract[26]	new[22]|new[24]|giv[26]	_	_
5-9	436-450	pharmaceutical	substance[22]|abstract[24]|abstract[26]	new[22]|new[24]|giv[26]	_	_
5-10	451-460	compounds	substance[22]|abstract[24]|abstract[26]	new[22]|new[24]|giv[26]	_	_
5-11	461-463	in	substance[22]|abstract[24]|abstract[26]	new[22]|new[24]|giv[26]	_	_
5-12	464-467	the	substance[22]|abstract[23]|abstract[24]|abstract[26]	new[22]|new[23]|new[24]|giv[26]	_	_
5-13	468-479	environment	substance[22]|abstract[23]|abstract[24]|abstract[26]	new[22]|new[23]|new[24]|giv[26]	_	_
5-14	480-482	is	abstract[24]|abstract[26]	new[24]|giv[26]	_	_
5-15	483-490	through	abstract[24]|abstract[26]	new[24]|giv[26]	_	_
5-16	491-501	industrial	abstract[24]|abstract[26]	new[24]|giv[26]	_	_
5-17	502-509	process	abstract[24]|abstract[26]	new[24]|giv[26]	_	_
5-18	510-515	water	substance|abstract[26]	new|giv[26]	_	_
5-19	516-525	discharge	abstract[26]	giv[26]	_	_
5-20	526-527	.	_	_	_	_

#Text=Several studies have shown that pharmaceutical drugs ( and their derived metabolites ) are found in effluents of wastewater treatment plants ( WWTPs ) and their removal is very inefficient .
6-1	528-535	Several	abstract[27]	new[27]	_	_
6-2	536-543	studies	abstract[27]	new[27]	_	_
6-3	544-548	have	_	_	_	_
6-4	549-554	shown	_	_	_	_
6-5	555-559	that	_	_	_	_
6-6	560-574	pharmaceutical	substance[28]|substance[29]	new[28]|new[29]	ana|coref|ana|coref	6-26[0_29]|7-7[40_28]|6-26[0_29]|7-7[40_28]
6-7	575-580	drugs	substance[28]|substance[29]	new[28]|new[29]	_	_
6-8	581-582	(	substance[29]	new[29]	_	_
6-9	583-586	and	substance[29]	new[29]	_	_
6-10	587-592	their	substance[29]|substance[30]	new[29]|new[30]	_	_
6-11	593-600	derived	substance[29]|substance[30]	new[29]|new[30]	_	_
6-12	601-612	metabolites	substance[29]|substance[30]	new[29]|new[30]	_	_
6-13	613-614	)	substance[29]	new[29]	_	_
6-14	615-618	are	_	_	_	_
6-15	619-624	found	_	_	_	_
6-16	625-627	in	_	_	_	_
6-17	628-637	effluents	person[31]	new[31]	_	_
6-18	638-640	of	person[31]	new[31]	_	_
6-19	641-651	wastewater	person[31]|substance|plant[34]	new[31]|giv|new[34]	coref|coref|coref|coref	7-1|10-14[67_34]|7-1|10-14[67_34]
6-20	652-661	treatment	person[31]|event|plant[34]	new[31]|new|new[34]	coref	10-16
6-21	662-668	plants	person[31]|plant[34]	new[31]|new[34]	_	_
6-22	669-670	(	_	_	_	_
6-23	671-676	WWTPs	object	new	_	_
6-24	677-678	)	_	_	_	_
6-25	679-682	and	_	_	_	_
6-26	683-688	their	substance|event[37]	giv|new[37]	coref|coref	16-17[106_37]|16-17[106_37]
6-27	689-696	removal	event[37]	new[37]	_	_
6-28	697-699	is	_	_	_	_
6-29	700-704	very	_	_	_	_
6-30	705-716	inefficient	_	_	_	_
6-31	717-718	.	_	_	_	_

#Text=Wastewater originating during the manufacturing of antidiabetic drugs is also an important environmental challenge due to the high production volume .
7-1	719-729	Wastewater	abstract	giv	coref	7-11[41_0]
7-2	730-741	originating	_	_	_	_
7-3	742-748	during	_	_	_	_
7-4	749-752	the	abstract[39]	giv[39]	_	_
7-5	753-766	manufacturing	abstract[39]	giv[39]	_	_
7-6	767-769	of	abstract[39]	giv[39]	_	_
7-7	770-782	antidiabetic	abstract[39]|substance[40]	giv[39]|giv[40]	coref	8-15[49_40]
7-8	783-788	drugs	abstract[39]|substance[40]	giv[39]|giv[40]	_	_
7-9	789-791	is	_	_	_	_
7-10	792-796	also	_	_	_	_
7-11	797-799	an	abstract[41]	giv[41]	coref	8-18[0_41]
7-12	800-809	important	abstract[41]	giv[41]	_	_
7-13	810-823	environmental	abstract[41]	giv[41]	_	_
7-14	824-833	challenge	abstract[41]	giv[41]	_	_
7-15	834-837	due	abstract[41]	giv[41]	_	_
7-16	838-840	to	_	_	_	_
7-17	841-844	the	quantity[43]	new[43]	_	_
7-18	845-849	high	quantity[43]	new[43]	_	_
7-19	850-860	production	abstract|quantity[43]	new|new[43]	_	_
7-20	861-867	volume	quantity[43]	new[43]	_	_
7-21	868-869	.	_	_	_	_

#Text=Several research papers have reported the occurrence , degradability , and environmental impact of antidiabetic drugs in wastewater , and substantial efforts to achieve environmental improvements in line with regulations and legislation have been implemented .
8-1	870-877	Several	object[45]	new[45]	_	_
8-2	878-886	research	abstract|object[45]	new|new[45]	_	_
8-3	887-893	papers	object[45]	new[45]	_	_
8-4	894-898	have	_	_	_	_
8-5	899-907	reported	_	_	_	_
8-6	908-911	the	abstract[46]	new[46]	_	_
8-7	912-922	occurrence	abstract[46]	new[46]	_	_
8-8	923-924	,	_	_	_	_
8-9	925-938	degradability	abstract	new	_	_
8-10	939-940	,	_	_	_	_
8-11	941-944	and	_	_	_	_
8-12	945-958	environmental	abstract[48]	new[48]	coref	9-6[57_48]
8-13	959-965	impact	abstract[48]	new[48]	_	_
8-14	966-968	of	abstract[48]	new[48]	_	_
8-15	969-981	antidiabetic	abstract[48]|substance[49]	new[48]|giv[49]	coref	9-8[58_49]
8-16	982-987	drugs	abstract[48]|substance[49]	new[48]|giv[49]	_	_
8-17	988-990	in	abstract[48]|substance[49]	new[48]|giv[49]	_	_
8-18	991-1001	wastewater	abstract[48]|substance[49]|substance	new[48]|giv[49]|giv	coref	10-15
8-19	1002-1003	,	_	_	_	_
8-20	1004-1007	and	_	_	_	_
8-21	1008-1019	substantial	event[51]	new[51]	_	_
8-22	1020-1027	efforts	event[51]	new[51]	_	_
8-23	1028-1030	to	_	_	_	_
8-24	1031-1038	achieve	_	_	_	_
8-25	1039-1052	environmental	abstract[52]	new[52]	_	_
8-26	1053-1065	improvements	abstract[52]	new[52]	_	_
8-27	1066-1068	in	abstract[52]	new[52]	_	_
8-28	1069-1073	line	abstract[52]	new[52]	_	_
8-29	1074-1078	with	abstract[52]	new[52]	_	_
8-30	1079-1090	regulations	abstract[52]|abstract	new[52]|new	_	_
8-31	1091-1094	and	abstract[52]	new[52]	_	_
8-32	1095-1106	legislation	abstract[52]|abstract	new[52]|new	_	_
8-33	1107-1111	have	_	_	_	_
8-34	1112-1116	been	_	_	_	_
8-35	1117-1128	implemented	_	_	_	_
8-36	1129-1130	.	_	_	_	_

#Text=Metformin ( C4H11N5 ) is one of the most prescribed and widely used antidiabetic drugs worldwide , since a significant portion of the population suffers from diabetes .
9-1	1131-1140	Metformin	abstract	new	appos	9-3
9-2	1141-1142	(	_	_	_	_
9-3	1143-1150	C4H11N5	abstract	giv	_	_
9-4	1151-1152	)	_	_	_	_
9-5	1153-1155	is	_	_	_	_
9-6	1156-1159	one	abstract[57]	giv[57]	_	_
9-7	1160-1162	of	abstract[57]	giv[57]	_	_
9-8	1163-1166	the	abstract[57]|substance[58]	giv[57]|giv[58]	_	_
9-9	1167-1171	most	abstract[57]|substance[58]	giv[57]|giv[58]	_	_
9-10	1172-1182	prescribed	abstract[57]|substance[58]	giv[57]|giv[58]	_	_
9-11	1183-1186	and	abstract[57]|substance[58]	giv[57]|giv[58]	_	_
9-12	1187-1193	widely	abstract[57]|substance[58]	giv[57]|giv[58]	_	_
9-13	1194-1198	used	abstract[57]|substance[58]	giv[57]|giv[58]	_	_
9-14	1199-1211	antidiabetic	abstract[57]|substance[58]	giv[57]|giv[58]	_	_
9-15	1212-1217	drugs	abstract[57]|substance[58]	giv[57]|giv[58]	_	_
9-16	1218-1227	worldwide	abstract[57]|substance[58]	giv[57]|giv[58]	_	_
9-17	1228-1229	,	_	_	_	_
9-18	1230-1235	since	_	_	_	_
9-19	1236-1237	a	quantity[59]	new[59]	ana	11-4[0_59]
9-20	1238-1249	significant	quantity[59]	new[59]	_	_
9-21	1250-1257	portion	quantity[59]	new[59]	_	_
9-22	1258-1260	of	quantity[59]	new[59]	_	_
9-23	1261-1264	the	quantity[59]|person[60]	new[59]|new[60]	_	_
9-24	1265-1275	population	quantity[59]|person[60]	new[59]|new[60]	_	_
9-25	1276-1283	suffers	_	_	_	_
9-26	1284-1288	from	_	_	_	_
9-27	1289-1297	diabetes	abstract	new	_	_
9-28	1298-1299	.	_	_	_	_

#Text=Recent reports have indicated that there are also high concentrations of metformin in domestic wastewater treatment plants ’ influent .
10-1	1300-1306	Recent	abstract[62]	new[62]	_	_
10-2	1307-1314	reports	abstract[62]	new[62]	_	_
10-3	1315-1319	have	_	_	_	_
10-4	1320-1329	indicated	_	_	_	_
10-5	1330-1334	that	_	_	_	_
10-6	1335-1340	there	_	_	_	_
10-7	1341-1344	are	_	_	_	_
10-8	1345-1349	also	_	_	_	_
10-9	1350-1354	high	abstract[63]	new[63]	_	_
10-10	1355-1369	concentrations	abstract[63]	new[63]	_	_
10-11	1370-1372	of	abstract[63]	new[63]	_	_
10-12	1373-1382	metformin	abstract[63]|substance[64]	new[63]|new[64]	ana	11-1[0_64]
10-13	1383-1385	in	abstract[63]|substance[64]	new[63]|new[64]	_	_
10-14	1386-1394	domestic	abstract[63]|substance[64]|plant[67]|person[68]	new[63]|new[64]|giv[67]|new[68]	coref|coref	15-21[99_67]|15-21[99_67]
10-15	1395-1405	wastewater	abstract[63]|substance[64]|substance|plant[67]|person[68]	new[63]|new[64]|giv|giv[67]|new[68]	coref	11-18
10-16	1406-1415	treatment	abstract[63]|substance[64]|event|plant[67]|person[68]	new[63]|new[64]|giv|giv[67]|new[68]	coref	13-7[85_0]
10-17	1416-1422	plants	abstract[63]|substance[64]|plant[67]|person[68]	new[63]|new[64]|giv[67]|new[68]	_	_
10-18	1423-1424	’	abstract[63]|substance[64]|plant[67]|person[68]	new[63]|new[64]|giv[67]|new[68]	_	_
10-19	1425-1433	influent	abstract[63]|substance[64]|person[68]	new[63]|new[64]|new[68]	_	_
10-20	1434-1435	.	_	_	_	_

#Text=This is because it is excreted un-metabolized from the human body in urine and ends up in wastewater and aquatic environments .
11-1	1436-1440	This	substance	giv	coref	12-1
11-2	1441-1443	is	_	_	_	_
11-3	1444-1451	because	_	_	_	_
11-4	1452-1454	it	quantity	giv	_	_
11-5	1455-1457	is	_	_	_	_
11-6	1458-1466	excreted	_	_	_	_
11-7	1467-1481	un-metabolized	_	_	_	_
11-8	1482-1486	from	_	_	_	_
11-9	1487-1490	the	object[71]	new[71]	_	_
11-10	1491-1496	human	object[71]	new[71]	_	_
11-11	1497-1501	body	object[71]	new[71]	_	_
11-12	1502-1504	in	object[71]	new[71]	_	_
11-13	1505-1510	urine	object[71]|substance	new[71]|new	_	_
11-14	1511-1514	and	_	_	_	_
11-15	1515-1519	ends	_	_	_	_
11-16	1520-1522	up	_	_	_	_
11-17	1523-1525	in	_	_	_	_
11-18	1526-1536	wastewater	substance|substance[74]	giv|giv[74]	coref|coref	12-11[79_0]|12-11[79_0]
11-19	1537-1540	and	substance[74]	giv[74]	_	_
11-20	1541-1548	aquatic	substance[74]|place[75]	giv[74]|new[75]	_	_
11-21	1549-1561	environments	substance[74]|place[75]	giv[74]|new[75]	_	_
11-22	1562-1563	.	_	_	_	_

#Text=Metformin is the pharmaceutical compound with the highest concentration in domestic wastewater ( i. e. , 64 – 98 µg/L ) .
12-1	1564-1573	Metformin	substance	giv	coref	12-3[77_0]
12-2	1574-1576	is	_	_	_	_
12-3	1577-1580	the	substance[77]	giv[77]	coref	15-1[0_77]
12-4	1581-1595	pharmaceutical	substance[77]	giv[77]	_	_
12-5	1596-1604	compound	substance[77]	giv[77]	_	_
12-6	1605-1609	with	substance[77]	giv[77]	_	_
12-7	1610-1613	the	substance[77]|abstract[78]	giv[77]|new[78]	_	_
12-8	1614-1621	highest	substance[77]|abstract[78]	giv[77]|new[78]	_	_
12-9	1622-1635	concentration	substance[77]|abstract[78]	giv[77]|new[78]	_	_
12-10	1636-1638	in	substance[77]|abstract[78]	giv[77]|new[78]	_	_
12-11	1639-1647	domestic	substance[77]|abstract[78]|substance[79]	giv[77]|new[78]|giv[79]	coref	13-7[0_79]
12-12	1648-1658	wastewater	substance[77]|abstract[78]|substance[79]	giv[77]|new[78]|giv[79]	_	_
12-13	1659-1660	(	_	_	_	_
12-14	1661-1663	i.	_	_	_	_
12-15	1664-1666	e.	_	_	_	_
12-16	1667-1668	,	_	_	_	_
12-17	1669-1671	64	quantity[80]	new[80]	_	_
12-18	1672-1673	–	quantity[80]	new[80]	_	_
12-19	1674-1676	98	quantity[80]|quantity	new[80]|new	_	_
12-20	1677-1681	µg/L	quantity[80]|quantity	new[80]|new	_	_
12-21	1682-1683	)	_	_	_	_
12-22	1684-1685	.	_	_	_	_

#Text=This study is therefore relevant for wastewater treatment in general , even though it is focused on metformin-containing industrial wastewater .
13-1	1686-1690	This	abstract[83]	new[83]	coref	17-5[110_83]
13-2	1691-1696	study	abstract[83]	new[83]	_	_
13-3	1697-1699	is	_	_	_	_
13-4	1700-1709	therefore	_	_	_	_
13-5	1710-1718	relevant	_	_	_	_
13-6	1719-1722	for	_	_	_	_
13-7	1723-1733	wastewater	substance|event[85]	giv|giv[85]	ana|coref|ana|coref	13-14[0_85]|13-18[88_0]|13-14[0_85]|13-18[88_0]
13-8	1734-1743	treatment	event[85]	giv[85]	_	_
13-9	1744-1746	in	_	_	_	_
13-10	1747-1754	general	person	new	_	_
13-11	1755-1756	,	_	_	_	_
13-12	1757-1761	even	_	_	_	_
13-13	1762-1768	though	_	_	_	_
13-14	1769-1771	it	event	giv	coref	15-22
13-15	1772-1774	is	_	_	_	_
13-16	1775-1782	focused	_	_	_	_
13-17	1783-1785	on	_	_	_	_
13-18	1786-1806	metformin-containing	substance[88]	giv[88]	coref	14-1[89_88]
13-19	1807-1817	industrial	substance[88]	giv[88]	_	_
13-20	1818-1828	wastewater	substance[88]	giv[88]	_	_
13-21	1829-1830	.	_	_	_	_

#Text=Pharmaceutical wastewater has traditionally been treated using conventional physico-chemical and biological process methods .
14-1	1831-1845	Pharmaceutical	substance[89]	giv[89]	coref	15-21[0_89]
14-2	1846-1856	wastewater	substance[89]	giv[89]	_	_
14-3	1857-1860	has	_	_	_	_
14-4	1861-1874	traditionally	_	_	_	_
14-5	1875-1879	been	_	_	_	_
14-6	1880-1887	treated	_	_	_	_
14-7	1888-1893	using	_	_	_	_
14-8	1894-1906	conventional	abstract[91]	new[91]	_	_
14-9	1907-1923	physico-chemical	abstract[91]	new[91]	_	_
14-10	1924-1927	and	abstract[91]	new[91]	_	_
14-11	1928-1938	biological	abstract[91]	new[91]	_	_
14-12	1939-1946	process	abstract|abstract[91]	giv|new[91]	coref	22-1[145_0]
14-13	1947-1954	methods	abstract[91]	new[91]	_	_
14-14	1955-1956	.	_	_	_	_

#Text=Metformin can be aerobically degraded to guanylurea ( C2H6N4O ) — a metabolite that is stable against further biodegradation in wastewater treatment plants .
15-1	1957-1966	Metformin	substance	giv	coref	16-21
15-2	1967-1970	can	_	_	_	_
15-3	1971-1973	be	_	_	_	_
15-4	1974-1985	aerobically	_	_	_	_
15-5	1986-1994	degraded	_	_	_	_
15-6	1995-1997	to	_	_	_	_
15-7	1998-2008	guanylurea	substance	new	appos	15-9
15-8	2009-2010	(	_	_	_	_
15-9	2011-2018	C2H6N4O	substance	giv	_	_
15-10	2019-2020	)	_	_	_	_
15-11	2021-2022	—	_	_	_	_
15-12	2023-2024	a	object[95]	new[95]	ana	16-3[0_95]
15-13	2025-2035	metabolite	object[95]	new[95]	_	_
15-14	2036-2040	that	_	_	_	_
15-15	2041-2043	is	_	_	_	_
15-16	2044-2050	stable	_	_	_	_
15-17	2051-2058	against	_	_	_	_
15-18	2059-2066	further	substance[96]	new[96]	_	_
15-19	2067-2081	biodegradation	substance[96]	new[96]	_	_
15-20	2082-2084	in	substance[96]	new[96]	_	_
15-21	2085-2095	wastewater	substance[96]|substance|plant[99]	new[96]|giv|giv[99]	coref|coref	24-1|24-1
15-22	2096-2105	treatment	substance[96]|event|plant[99]	new[96]|giv|giv[99]	coref	25-8[163_0]
15-23	2106-2112	plants	substance[96]|plant[99]	new[96]|giv[99]	_	_
15-24	2113-2114	.	_	_	_	_

#Text=However , it appears to be a novel idea to integrate anaerobic and aerobic processes for the efficient removal of metformin and other pharmaceutical constituents .
16-1	2115-2122	However	_	_	_	_
16-2	2123-2124	,	_	_	_	_
16-3	2125-2127	it	object	giv	_	_
16-4	2128-2135	appears	_	_	_	_
16-5	2136-2138	to	_	_	_	_
16-6	2139-2141	be	_	_	_	_
16-7	2142-2143	a	abstract[101]	new[101]	_	_
16-8	2144-2149	novel	abstract[101]	new[101]	_	_
16-9	2150-2154	idea	abstract[101]	new[101]	_	_
16-10	2155-2157	to	_	_	_	_
16-11	2158-2167	integrate	_	_	_	_
16-12	2168-2177	anaerobic	substance|abstract[103]	new|new[103]	coref|coref|coref|coref	17-9|23-8[153_103]|17-9|23-8[153_103]
16-13	2178-2181	and	abstract[103]	new[103]	_	_
16-14	2182-2189	aerobic	abstract[103]|abstract|abstract[105]	new[103]|new|giv[105]	coref|coref|coref|coref	17-13|23-11[154_105]|17-13|23-11[154_105]
16-15	2190-2199	processes	abstract[103]|abstract[105]	new[103]|giv[105]	_	_
16-16	2200-2203	for	_	_	_	_
16-17	2204-2207	the	event[106]	giv[106]	coref	29-45[0_106]
16-18	2208-2217	efficient	event[106]	giv[106]	_	_
16-19	2218-2225	removal	event[106]	giv[106]	_	_
16-20	2226-2228	of	event[106]	giv[106]	_	_
16-21	2229-2238	metformin	event[106]|substance	giv[106]|giv	coref	29-36
16-22	2239-2242	and	event[106]	giv[106]	_	_
16-23	2243-2248	other	event[106]|substance[108]	giv[106]|new[108]	coref	22-6[146_108]
16-24	2249-2263	pharmaceutical	event[106]|substance[108]	giv[106]|new[108]	_	_
16-25	2264-2276	constituents	event[106]|substance[108]	giv[106]|new[108]	_	_
16-26	2277-2278	.	_	_	_	_

#Text=The basic hypothesis of this study is that anaerobic granular sludge and aerobic biofilms supported by a hybrid vertical anaerobic biofilm ( HyVAB® ) reactor design (
17-1	2279-2282	The	abstract[109]	new[109]	_	_
17-2	2283-2288	basic	abstract[109]	new[109]	_	_
17-3	2289-2299	hypothesis	abstract[109]	new[109]	_	_
17-4	2300-2302	of	abstract[109]	new[109]	_	_
17-5	2303-2307	this	abstract[109]|abstract[110]	new[109]|giv[110]	coref	29-2[188_110]
17-6	2308-2313	study	abstract[109]|abstract[110]	new[109]|giv[110]	_	_
17-7	2314-2316	is	_	_	_	_
17-8	2317-2321	that	_	_	_	_
17-9	2322-2331	anaerobic	abstract|substance[112]	giv|new[112]	coref|coref	17-20|17-20
17-10	2332-2340	granular	substance[112]	new[112]	_	_
17-11	2341-2347	sludge	substance[112]	new[112]	_	_
17-12	2348-2351	and	_	_	_	_
17-13	2352-2359	aerobic	abstract|substance[114]	giv|new[114]	coref|coref	27-2|27-2
17-14	2360-2368	biofilms	substance[114]	new[114]	_	_
17-15	2369-2378	supported	_	_	_	_
17-16	2379-2381	by	_	_	_	_
17-17	2382-2383	a	abstract[116]	new[116]	appos	17-23[0_116]
17-18	2384-2390	hybrid	abstract[116]	new[116]	_	_
17-19	2391-2399	vertical	abstract[116]	new[116]	_	_
17-20	2400-2409	anaerobic	abstract|abstract[116]	giv|new[116]	coref	23-8[152_0]
17-21	2410-2417	biofilm	abstract[116]	new[116]	_	_
17-22	2418-2419	(	_	_	_	_
17-23	2420-2426	HyVAB®	abstract	giv	coref	23-1
17-24	2427-2428	)	_	_	_	_
17-25	2429-2436	reactor	person|abstract[119]	new|new[119]	_	_
17-26	2437-2443	design	abstract[119]	new[119]	_	_
17-27	2444-2445	(	_	_	_	_

#Text=Figure 1
18-1	2446-2452	Figure	object[120]	new[120]	_	_
18-2	2453-2454	1	object[120]	new[120]	_	_

#Text=) are the most robust combined niches for microorganisms to treat inhibitory substances , since microbial aggregates protect the microorganisms against such substances as they are delivered slowly by diffusion from the liquid phase .
19-1	2455-2456	)	_	_	_	_
19-2	2457-2460	are	_	_	_	_
19-3	2461-2464	the	abstract[121]	new[121]	ana	19-25[0_121]
19-4	2465-2469	most	abstract[121]	new[121]	_	_
19-5	2470-2476	robust	abstract[121]	new[121]	_	_
19-6	2477-2485	combined	abstract[121]	new[121]	_	_
19-7	2486-2492	niches	abstract[121]	new[121]	_	_
19-8	2493-2496	for	abstract[121]	new[121]	_	_
19-9	2497-2511	microorganisms	abstract[121]|animal	new[121]|new	coref	19-19[125_0]
19-10	2512-2514	to	_	_	_	_
19-11	2515-2520	treat	_	_	_	_
19-12	2521-2531	inhibitory	substance[123]	new[123]	coref	19-22[126_123]
19-13	2532-2542	substances	substance[123]	new[123]	_	_
19-14	2543-2544	,	_	_	_	_
19-15	2545-2550	since	_	_	_	_
19-16	2551-2560	microbial	object[124]	new[124]	coref	22-16[149_124]
19-17	2561-2571	aggregates	object[124]	new[124]	_	_
19-18	2572-2579	protect	_	_	_	_
19-19	2580-2583	the	animal[125]	giv[125]	_	_
19-20	2584-2598	microorganisms	animal[125]	giv[125]	_	_
19-21	2599-2606	against	animal[125]	giv[125]	_	_
19-22	2607-2611	such	animal[125]|substance[126]	giv[125]|giv[126]	_	_
19-23	2612-2622	substances	animal[125]|substance[126]	giv[125]|giv[126]	_	_
19-24	2623-2625	as	_	_	_	_
19-25	2626-2630	they	abstract	giv	_	_
19-26	2631-2634	are	_	_	_	_
19-27	2635-2644	delivered	_	_	_	_
19-28	2645-2651	slowly	_	_	_	_
19-29	2652-2654	by	_	_	_	_
19-30	2655-2664	diffusion	abstract[128]	new[128]	_	_
19-31	2665-2669	from	abstract[128]	new[128]	_	_
19-32	2670-2673	the	abstract[128]|abstract[130]	new[128]|new[130]	coref	21-28[143_130]
19-33	2674-2680	liquid	abstract[128]|substance|abstract[130]	new[128]|new|new[130]	_	_
19-34	2681-2686	phase	abstract[128]|abstract[130]	new[128]|new[130]	_	_
19-35	2687-2688	.	_	_	_	_

#Text=The more sensitive organisms are in the deeper layers protected by layers of organisms embedded in an extracellular polymeric matrix .
20-1	2689-2692	The	animal[131]	new[131]	coref	20-14[0_131]
20-2	2693-2697	more	animal[131]	new[131]	_	_
20-3	2698-2707	sensitive	animal[131]	new[131]	_	_
20-4	2708-2717	organisms	animal[131]	new[131]	_	_
20-5	2718-2721	are	_	_	_	_
20-6	2722-2724	in	_	_	_	_
20-7	2725-2728	the	abstract[132]	new[132]	coref	20-12[133_132]
20-8	2729-2735	deeper	abstract[132]	new[132]	_	_
20-9	2736-2742	layers	abstract[132]	new[132]	_	_
20-10	2743-2752	protected	_	_	_	_
20-11	2753-2755	by	_	_	_	_
20-12	2756-2762	layers	abstract[133]	giv[133]	_	_
20-13	2763-2765	of	abstract[133]	giv[133]	_	_
20-14	2766-2775	organisms	abstract[133]|animal	giv[133]|giv	_	_
20-15	2776-2784	embedded	_	_	_	_
20-16	2785-2787	in	_	_	_	_
20-17	2788-2790	an	substance[135]	new[135]	coref	22-11[148_135]
20-18	2791-2804	extracellular	substance[135]	new[135]	_	_
20-19	2805-2814	polymeric	substance[135]	new[135]	_	_
20-20	2815-2821	matrix	substance[135]	new[135]	_	_
20-21	2822-2823	.	_	_	_	_

#Text=Adaptation to toxic chemicals can be slow and can go through the stages of survival , tolerance , capture , and — if at all biodegradable — the final adaptation stage is degradation .
21-1	2824-2834	Adaptation	abstract[136]	new[136]	coref	21-30[0_136]
21-2	2835-2837	to	abstract[136]	new[136]	_	_
21-3	2838-2843	toxic	abstract[136]|substance[137]	new[136]|new[137]	_	_
21-4	2844-2853	chemicals	abstract[136]|substance[137]	new[136]|new[137]	_	_
21-5	2854-2857	can	_	_	_	_
21-6	2858-2860	be	_	_	_	_
21-7	2861-2865	slow	_	_	_	_
21-8	2866-2869	and	_	_	_	_
21-9	2870-2873	can	_	_	_	_
21-10	2874-2876	go	_	_	_	_
21-11	2877-2884	through	_	_	_	_
21-12	2885-2888	the	abstract[138]	new[138]	_	_
21-13	2889-2895	stages	abstract[138]	new[138]	_	_
21-14	2896-2898	of	abstract[138]	new[138]	_	_
21-15	2899-2907	survival	abstract[138]|event	new[138]|new	_	_
21-16	2908-2909	,	abstract[138]	new[138]	_	_
21-17	2910-2919	tolerance	abstract[138]|abstract	new[138]|new	_	_
21-18	2920-2921	,	abstract[138]	new[138]	_	_
21-19	2922-2929	capture	abstract[138]|event	new[138]|new	_	_
21-20	2930-2931	,	_	_	_	_
21-21	2932-2935	and	_	_	_	_
21-22	2936-2937	—	_	_	_	_
21-23	2938-2940	if	_	_	_	_
21-24	2941-2943	at	_	_	_	_
21-25	2944-2947	all	_	_	_	_
21-26	2948-2961	biodegradable	_	_	_	_
21-27	2962-2963	—	_	_	_	_
21-28	2964-2967	the	abstract[143]	giv[143]	coref	21-33[0_143]
21-29	2968-2973	final	abstract[143]	giv[143]	_	_
21-30	2974-2984	adaptation	abstract|abstract[143]	giv|giv[143]	_	_
21-31	2985-2990	stage	abstract[143]	giv[143]	_	_
21-32	2991-2993	is	_	_	_	_
21-33	2994-3005	degradation	abstract	giv	coref	24-12
21-34	3006-3007	.	_	_	_	_

#Text=The process can even remove non-biodegradable constituents by integration in the extracellular matrix to build more aggregates .
22-1	3008-3011	The	abstract[145]	giv[145]	coref	27-8[178_145]
22-2	3012-3019	process	abstract[145]	giv[145]	_	_
22-3	3020-3023	can	_	_	_	_
22-4	3024-3028	even	_	_	_	_
22-5	3029-3035	remove	_	_	_	_
22-6	3036-3053	non-biodegradable	substance[146]	giv[146]	_	_
22-7	3054-3066	constituents	substance[146]	giv[146]	_	_
22-8	3067-3069	by	_	_	_	_
22-9	3070-3081	integration	abstract[147]	new[147]	_	_
22-10	3082-3084	in	abstract[147]	new[147]	_	_
22-11	3085-3088	the	abstract[147]|substance[148]	new[147]|giv[148]	_	_
22-12	3089-3102	extracellular	abstract[147]|substance[148]	new[147]|giv[148]	_	_
22-13	3103-3109	matrix	abstract[147]|substance[148]	new[147]|giv[148]	_	_
22-14	3110-3112	to	_	_	_	_
22-15	3113-3118	build	_	_	_	_
22-16	3119-3123	more	object[149]	giv[149]	_	_
22-17	3124-3134	aggregates	object[149]	giv[149]	_	_
22-18	3135-3136	.	_	_	_	_

#Text=HyVAB® is a compact reactor that integrates both anaerobic and aerobic processes .
23-1	3137-3143	HyVAB®	abstract	giv	coref	23-3[151_0]
23-2	3144-3146	is	_	_	_	_
23-3	3147-3148	a	object[151]	giv[151]	coref	25-13[0_151]
23-4	3149-3156	compact	object[151]	giv[151]	_	_
23-5	3157-3164	reactor	object[151]	giv[151]	_	_
23-6	3165-3169	that	_	_	_	_
23-7	3170-3180	integrates	_	_	_	_
23-8	3181-3185	both	substance[152]|abstract[153]	giv[152]|giv[153]	coref|coref	24-7[0_152]|24-7[0_152]
23-9	3186-3195	anaerobic	substance[152]|abstract[153]	giv[152]|giv[153]	_	_
23-10	3196-3199	and	abstract[153]	giv[153]	_	_
23-11	3200-3207	aerobic	abstract[153]|abstract[154]	giv[153]|giv[154]	_	_
23-12	3208-3217	processes	abstract[153]|abstract[154]	giv[153]|giv[154]	_	_
23-13	3218-3219	.	_	_	_	_

#Text=Wastewater is introduced at the bottom anaerobic digestion ( AD ) stage , where organic matter is degraded and converted into methane .
24-1	3220-3230	Wastewater	substance	giv	coref	29-8
24-2	3231-3233	is	_	_	_	_
24-3	3234-3244	introduced	_	_	_	_
24-4	3245-3247	at	_	_	_	_
24-5	3248-3251	the	abstract[157]	new[157]	appos	24-10[0_157]
24-6	3252-3258	bottom	abstract[157]	new[157]	_	_
24-7	3259-3268	anaerobic	substance|abstract[157]	giv|new[157]	_	_
24-8	3269-3278	digestion	abstract[157]	new[157]	_	_
24-9	3279-3280	(	_	_	_	_
24-10	3281-3283	AD	abstract	giv	coref	28-13
24-11	3284-3285	)	_	_	_	_
24-12	3286-3291	stage	abstract	giv	coref	25-11[165_0]
24-13	3292-3293	,	_	_	_	_
24-14	3294-3299	where	_	_	_	_
24-15	3300-3307	organic	substance[160]	new[160]	_	_
24-16	3308-3314	matter	substance[160]	new[160]	_	_
24-17	3315-3317	is	_	_	_	_
24-18	3318-3326	degraded	_	_	_	_
24-19	3327-3330	and	_	_	_	_
24-20	3331-3340	converted	_	_	_	_
24-21	3341-3345	into	_	_	_	_
24-22	3346-3353	methane	substance	new	_	_
24-23	3354-3355	.	_	_	_	_

#Text=The remaining unconsumed organics flow up for further treatment in the aerobic biofilm stage designed as a Continuous Flow Intermittent Cleaning ( CFIC® ) .
25-1	3356-3359	The	substance[162]	new[162]	_	_
25-2	3360-3369	remaining	substance[162]	new[162]	_	_
25-3	3370-3380	unconsumed	substance[162]	new[162]	_	_
25-4	3381-3389	organics	substance[162]	new[162]	_	_
25-5	3390-3394	flow	_	_	_	_
25-6	3395-3397	up	_	_	_	_
25-7	3398-3401	for	_	_	_	_
25-8	3402-3409	further	event[163]	giv[163]	_	_
25-9	3410-3419	treatment	event[163]	giv[163]	_	_
25-10	3420-3422	in	event[163]	giv[163]	_	_
25-11	3423-3426	the	event[163]|abstract[165]	giv[163]|giv[165]	coref	26-9[172_165]
25-12	3427-3434	aerobic	event[163]|abstract[165]	giv[163]|giv[165]	_	_
25-13	3435-3442	biofilm	event[163]|abstract|abstract[165]	giv[163]|giv|giv[165]	coref	26-6
25-14	3443-3448	stage	event[163]|abstract[165]	giv[163]|giv[165]	_	_
25-15	3449-3457	designed	_	_	_	_
25-16	3458-3460	as	_	_	_	_
25-17	3461-3462	a	_	_	_	_
25-18	3463-3473	Continuous	_	_	_	_
25-19	3474-3478	Flow	abstract	new	_	_
25-20	3479-3491	Intermittent	organization	new	_	_
25-21	3492-3500	Cleaning	_	_	_	_
25-22	3501-3502	(	_	_	_	_
25-23	3503-3508	CFIC®	abstract	new	coref	27-16
25-24	3509-3510	)	_	_	_	_
25-25	3511-3512	.	_	_	_	_

#Text=Plastic bio-carriers serve as a biofilm substratum in the aerobic biofilm stage , protecting the biofilm from shear force .
26-1	3513-3520	Plastic	object[169]	new[169]	_	_
26-2	3521-3533	bio-carriers	object[169]	new[169]	_	_
26-3	3534-3539	serve	_	_	_	_
26-4	3540-3542	as	_	_	_	_
26-5	3543-3544	a	_	_	_	_
26-6	3545-3552	biofilm	abstract	giv	coref	26-11
26-7	3553-3563	substratum	_	_	_	_
26-8	3564-3566	in	_	_	_	_
26-9	3567-3570	the	abstract[172]	giv[172]	coref	28-12[183_172]
26-10	3571-3578	aerobic	abstract[172]	giv[172]	_	_
26-11	3579-3586	biofilm	abstract|abstract[172]	giv|giv[172]	coref	26-15[173_0]
26-12	3587-3592	stage	abstract[172]	giv[172]	_	_
26-13	3593-3594	,	_	_	_	_
26-14	3595-3605	protecting	_	_	_	_
26-15	3606-3609	the	abstract[173]	giv[173]	coref	28-16[184_173]
26-16	3610-3617	biofilm	abstract[173]	giv[173]	_	_
26-17	3618-3622	from	_	_	_	_
26-18	3623-3628	shear	abstract[174]	new[174]	_	_
26-19	3629-3634	force	abstract[174]	new[174]	_	_
26-20	3635-3636	.	_	_	_	_

#Text=Excess aerobic sludge is washed off during the intermittent washing process ( i. e. , CFIC® ) .
27-1	3637-3643	Excess	substance[176]	new[176]	_	_
27-2	3644-3651	aerobic	abstract|substance[176]	giv|new[176]	_	_
27-3	3652-3658	sludge	substance[176]	new[176]	_	_
27-4	3659-3661	is	_	_	_	_
27-5	3662-3668	washed	_	_	_	_
27-6	3669-3672	off	_	_	_	_
27-7	3673-3679	during	_	_	_	_
27-8	3680-3683	the	abstract[178]	giv[178]	_	_
27-9	3684-3696	intermittent	abstract[178]	giv[178]	_	_
27-10	3697-3704	washing	abstract|abstract[178]	new|giv[178]	_	_
27-11	3705-3712	process	abstract[178]	giv[178]	_	_
27-12	3713-3714	(	_	_	_	_
27-13	3715-3717	i.	_	_	_	_
27-14	3718-3720	e.	_	_	_	_
27-15	3721-3722	,	_	_	_	_
27-16	3723-3728	CFIC®	abstract	giv	_	_
27-17	3729-3730	)	_	_	_	_
27-18	3731-3732	.	_	_	_	_

#Text=Part of the detached aerobic biofilm settles down by gravity to the AD stage in the HyVAB® , where it is degraded simultaneously with the feed substrates .
28-1	3733-3737	Part	_	_	_	_
28-2	3738-3740	of	_	_	_	_
28-3	3741-3744	the	substance[180]	new[180]	ana	28-20[0_180]
28-4	3745-3753	detached	substance[180]	new[180]	_	_
28-5	3754-3761	aerobic	substance[180]	new[180]	_	_
28-6	3762-3769	biofilm	substance[180]	new[180]	_	_
28-7	3770-3777	settles	_	_	_	_
28-8	3778-3782	down	_	_	_	_
28-9	3783-3785	by	_	_	_	_
28-10	3786-3793	gravity	abstract	new	_	_
28-11	3794-3796	to	_	_	_	_
28-12	3797-3800	the	abstract[183]	giv[183]	_	_
28-13	3801-3803	AD	abstract|abstract[183]	giv|giv[183]	_	_
28-14	3804-3809	stage	abstract[183]	giv[183]	_	_
28-15	3810-3812	in	abstract[183]	giv[183]	_	_
28-16	3813-3816	the	abstract[183]|abstract[184]	giv[183]|giv[184]	coref	29-25[196_184]
28-17	3817-3823	HyVAB®	abstract[183]|abstract[184]	giv[183]|giv[184]	_	_
28-18	3824-3825	,	_	_	_	_
28-19	3826-3831	where	_	_	_	_
28-20	3832-3834	it	substance	giv	_	_
28-21	3835-3837	is	_	_	_	_
28-22	3838-3846	degraded	_	_	_	_
28-23	3847-3861	simultaneously	_	_	_	_
28-24	3862-3866	with	_	_	_	_
28-25	3867-3870	the	object[187]	new[187]	_	_
28-26	3871-3875	feed	substance|object[187]	new|new[187]	_	_
28-27	3876-3886	substrates	object[187]	new[187]	_	_
28-28	3887-3888	.	_	_	_	_

#Text=In this study , two types of wastewater — wastewater I ( WWI ) and wastewater II ( WWII ) — were fed to the reactor , and performance was evaluated on the basis of metformin reduction , chemical oxygen demand ( COD ) removal efficiency , and biogas production .
29-1	3889-3891	In	_	_	_	_
29-2	3892-3896	this	event[188]	giv[188]	_	_
29-3	3897-3902	study	event[188]	giv[188]	_	_
29-4	3903-3904	,	_	_	_	_
29-5	3905-3908	two	place[189]	new[189]	_	_
29-6	3909-3914	types	place[189]	new[189]	_	_
29-7	3915-3917	of	place[189]	new[189]	_	_
29-8	3918-3928	wastewater	place[189]|substance	new[189]|giv	coref	29-10
29-9	3929-3930	—	_	_	_	_
29-10	3931-3941	wastewater	substance|abstract[192]	giv|new[192]	coref|coref	29-16[194_0]|29-16[194_0]
29-11	3942-3943	I	abstract[192]	new[192]	_	_
29-12	3944-3945	(	_	_	_	_
29-13	3946-3949	WWI	event	new	_	_
29-14	3950-3951	)	_	_	_	_
29-15	3952-3955	and	_	_	_	_
29-16	3956-3966	wastewater	substance[194]	giv[194]	_	_
29-17	3967-3969	II	substance[194]	giv[194]	_	_
29-18	3970-3971	(	_	_	_	_
29-19	3972-3976	WWII	event	new	_	_
29-20	3977-3978	)	_	_	_	_
29-21	3979-3980	—	_	_	_	_
29-22	3981-3985	were	_	_	_	_
29-23	3986-3989	fed	_	_	_	_
29-24	3990-3992	to	_	_	_	_
29-25	3993-3996	the	object[196]	giv[196]	_	_
29-26	3997-4004	reactor	object[196]	giv[196]	_	_
29-27	4005-4006	,	_	_	_	_
29-28	4007-4010	and	_	_	_	_
29-29	4011-4022	performance	abstract	new	_	_
29-30	4023-4026	was	_	_	_	_
29-31	4027-4036	evaluated	_	_	_	_
29-32	4037-4039	on	_	_	_	_
29-33	4040-4043	the	abstract[198]	new[198]	_	_
29-34	4044-4049	basis	abstract[198]	new[198]	_	_
29-35	4050-4052	of	abstract[198]	new[198]	_	_
29-36	4053-4062	metformin	abstract[198]|substance|abstract[200]	new[198]|giv|new[200]	_	_
29-37	4063-4072	reduction	abstract[198]|abstract[200]	new[198]|new[200]	_	_
29-38	4073-4074	,	abstract[198]	new[198]	_	_
29-39	4075-4083	chemical	abstract[198]|abstract[202]	new[198]|new[202]	_	_
29-40	4084-4090	oxygen	abstract[198]|substance|abstract[202]	new[198]|new|new[202]	_	_
29-41	4091-4097	demand	abstract[198]|abstract[202]	new[198]|new[202]	_	_
29-42	4098-4099	(	abstract[198]|abstract[205]	new[198]|new[205]	_	_
29-43	4100-4103	COD	abstract[198]|substance|abstract[205]	new[198]|new|new[205]	_	_
29-44	4104-4105	)	abstract[198]|abstract[205]	new[198]|new[205]	_	_
29-45	4106-4113	removal	abstract[198]|event|abstract[205]	new[198]|giv|new[205]	_	_
29-46	4114-4124	efficiency	abstract[198]|abstract[205]	new[198]|new[205]	_	_
29-47	4125-4126	,	abstract[198]	new[198]	_	_
29-48	4127-4130	and	abstract[198]	new[198]	_	_
29-49	4131-4137	biogas	abstract[198]|substance|abstract[207]	new[198]|new|new[207]	_	_
29-50	4138-4148	production	abstract[198]|abstract[207]	new[198]|new[207]	_	_
29-51	4149-4150	.	_	_	_	_
